Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.

Jobst C. von Einem,Christine Guenther,Hans-Dieter Volk,Gerald Gruetz,Daniela Hirsch,Christoph Salat,Oliver J. Stoetzer,Peter J. Nelson,Marlies Michl,Dominik Paul Modest,Julian Walter Holch,Martin K. Angele,Christiane J. Bruns,Hanno Niess,Volker Heinemann

Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.

2019

Jobst C. von Einem
Christine Guenther
Hans-Dieter Volk
Gerald Gruetz
Daniela Hirsch
Christoph Salat
Oliver J. Stoetzer
Peter J. Nelson
Marlies Michl
Dominik Paul Modest
Julian Walter Holch
Martin K. Angele
Christiane J. Bruns
Hanno Niess
Volker Heinemann

e14648Background: TREAT-ME-1, a Phase 1/2 open-label, first-in-human, first-in-class trial, evaluated the safety, tolerability and efficacy of treatment with genetically modified autologous mesench...

Keywords:

Cancer research
Gastrointestinal cancer
Mesenchymal stem cell
Genetically modified organism
Pathology
Medicine
Tolerability
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations